Triple threat: new combo aims to outsmart resistant colorectal cancer
Disease control
Recruiting now
This early-stage trial tests a combination of three treatments for people with advanced colorectal cancer who have already tried two standard therapies. The approach combines a special immune cell therapy (DC-CIK), an immunotherapy drug, and a targeted pill to attack the cancer f…
Phase: EARLY_PHASE1 • Sponsor: JIANG LONGWEI • Aim: Disease control
Last updated May 17, 2026 02:56 UTC